In gratitude of the loyal support of our members, the CNS is offering complimentary 2021 Annual Meeting registration to all members! Learn more.

  • Efficacy and safety of higher dose stereotactic radiosurgery for functional pituitary adenomas: A preliminary report

    Final Number:

    Ryan Grant MD, MS; Margaret Whicker; Ranee Lleva MD; Jonathan P.S. Knisely MD, FRCP; Silvio Inzucchi; Veronica Chiang MD

    Study Design:

    Subject Category:

    Meeting: Congress of Neurological Surgeons 2012 Annual Meeting

    Introduction: Single fraction stereotactic radiosurgery (SRS) is a common adjuvant therapy for hormonally active pituitary adenomas when surgical resection fails to control tumor growth or normalize hypersecretory activity. Marginal doses of 20 – 24 Gy are used at many centers and hormonal normalization commonly occurs in about 50% of patients by 30 – 50 months. We report out outcome data for patients treated with a higher marginal dose of 35 Gy.

    Methods: 31 patients with secretory pituitary adenomas (ACTH: n = 15, GH: n = 13, PRL: n = 2, TSH: n = 1) were treated with 35 Gy to the 50% isodose surface, with a mean follow-up of 39.2 months. All patients were evaluated post-SRS for time to normalization of hormonal secretion, time to relapse, and incidence of radiation-induced hypopituitarism and cranial neuropathies.

    Results: Normalization of hypersecretion was achieved in 22 patients (70.1%) with a median time to remission of 17.7 months. There was 100% tumor control and 7 patients (31.8%) experienced an endocrine relapse, with a mean relapse time of 21 months. There was a small positive correlation between the percent of tumor receiving > 48 Gy and remission time (r = 0.28). New endocrine deficiency within any hormonal axis was observed in 10 patients (32.3%), with a mean time to any endocrine deficiency of 11.7 months. Three patients (9.7%) reported transient frontal headaches of unclear etiology following the procedure, with 1 of these patients (3.2%) reporting pain in a V1-V2 distribution.

    Conclusions: Time to endocrine remission was more rapid in our patients treated with 35 Gy to the tumor margin when compared to the previously reported literature using marginal doses of 20-24 Gy. Rates of endocrine remission and relapse, post-SRS hypopituitarism, and radiation-induced sequelae were not increased when using the higher dose treatment.

    Patient Care: SRS at higher doses will allow patients to have faster remission rates, reduce symptoms, and permit discontinuation of anti-pituitary medications earlier. This in turn greatly improves quality of life of our patients.

    Learning Objectives: Stereotactic gamma-knife radiation for secreting pituitary adenomas can be given at higher doses, with faster remission rates without an increase in morbidity.


We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site. Privacy Policy